Knut Elbers
Project Manager @ Boehringer Ingelheim Venture Fund
Frankfurt, Germany
Knut Elbers is a Series B investor at Boehringer Ingelheim Venture Fund in Frankfurt focused on Biopharma and Life Science. Knut Elbers joined Boehringer Ingelheim as Project Manager.
Last updated:
For AI agents: llms.txt
Industries Knut Elbers invests in
Stages Knut Elbers invests in
Countries Knut Elbers invests in
Investment Focus
Industry
- Biopharma 1 (0%)
- Life Science 1 (0%)
- Neuroscience 1 (0%)
- Therapeutics 1 (0%)
- Biotechnology 1 (0%)
About Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Boehringer Ingelheim Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Debbie Lin
Executive Director
|
|||
|
Knut Elbers
Project Manager
|
|||
Martin Heidecker
Managing Director
|
|||
Oliver Reuss
Executive Director and Investment Manager
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Knut Elbers invest in?
Knut Elbers invests primarily in Biopharma, Life Science and Neuroscience startups, most often at Series B stage. Most of the 0 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
